**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!

The growing MedTech arena is home to some notable players... The growing MedTech arena is home to some notable players...                                                                                                      You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please [unsubscribe]( here. This message is from Huge Alerts. --------------------------------------------------------------- **Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! [BSEM]( [Revenues continue to explode for this growing MedTech firm that just got another price increase from Zack’s Small Cap Research to $23.25!]( The growing MedTech arena is home to some notable players but one company is uniquely standing out as its revenues explode, purchase orders accelerate, and a price target from Zack’s Small Cap Research continues to move north. BioStem Technologies, Inc. (BSEM) is changing the skin graft market by using the natural properties of perinatal tissue. Growth is rocketing as management makes smart and aggressive moves. Following 2023, a year of tremendous growth, BSEM recently released its Q1 financial results of $ 41 million that revealed the company’s first positive net income! BSEM attributes its growth to the successful launch of the company’s Amniowrap2™, an innovative placental-derived allograft product designed to address a broad spectrum of wound applications. A significant factor contributing to this success has been the widespread acceptance and utilization of Amniowrap2™ by medical professionals, underscoring its effectiveness and growing prominence in the healthcare industry. [BSEM especially gained momentum in the second half of 2023 when the Centers awarded the company a valuable Q code for its Vendaje AC and AmnioWrap2 products for Medicare and Medicaid Services.](Most recently, the company announced that its Healthcare Common Procedure Coding System code for Vendaje AC became effective and that the Center for Medicare Services established national pricing for AmnioWrap2 in all 50 states and territories. Additionally, the company isn’t resting on its success as management recently initiated a clinical trial evaluating Vendaje in diabetic foot ulcers—a market with enormous and growing potential! BSEM additionally sees an uplisting to a major exchange sooner than later! [Learn more about why Zack’s has increased its price target on BSEM to a whopping $23.25!]( Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Biostem Technologies Inc. (OTC:BSEM). The compensation consists of up to $2,500 and was received/will be received from Sideways Frequency. This compensation should not be considered as an endorsement of the securities of adviser Biostem Technologies Inc. (OTC:BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of Biostem Technologies Inc. (OTC:BSEM). We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 6/5/24. Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Unsubscribe](